Skip to main content

Treatment of Psychiatric Disorders such as PTSD, Impulse Control Difficulties, Emotional Dysregulation, PMS, Anxiety, Hypervigilance and Sleep Issues.

Description:

It is widely recognized that the endogenous opioid system plays a major role in the mammalian neuro-psychobiology, but to date, pharmacological interventions affecting this system have been mostly ineffective or carry a burden of serious side effects. While there is promise of better pharmaceuticals to come, it appears that in LDN we already have a medication that safely and effectively reduces psychiatric symptoms through subtle manipulation of the endogenous opioid system. 

Using multiple case studies, this session will illustrate how LDN can be used as an adjunct in psychotherapy to address a variety of psychiatric issues, without the side effects associated with other psychotropic medications. LDN can significantly reduce psychiatric symptoms, but its effects are subtle and it is common for patients to discontinue use of the medication even though they may be experiencing a benefit. The presenter will identify a strategy for effectively initiating and maintaining use of LDN for treatment of psychiatric disorders, describe dosing considerations and address safety and medical risks factors. The presentation will also identify the apparent benefits of a constant partial blockade strategy compared to an intermittent blockade of opioid receptors for reducing dissociative phenomena. Relevant research will be highlighted.  

Biography:

Galyn Forster MS is a Licensed Professional Counselor practicing in Eugene Oregon since receiving an M.S. in Counseling Psychology from the University of Oregon in 1988. He works with adults, youth and couples with a wide range of issues including complex trauma, dissociation, anxiety, attachment issues, physical pain and unexplained somatic complaints. His clinical theoretical orientation is eclectic but central are the therapies of Eye Movement Desensitization (EMDR), Coherence Therapy and Acceptance and Commitment Therapy (ACT) and Sensorimotor Therapy.

He began working with patients prescribed low dose naltrexone (LDN) as an adjunct to psychotherapy in 2010. Since then, he has worked with more than thirty-five patients using LDN to help manage psychiatric symptoms.